In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Redefining An Incubator

Executive Summary

For many device start-ups, incubators have been critical to an early, efficient launch of their company. Unfortunately, the financial model behind incubators hasn't always been so generous to the incubators themselves. Now, a leading incubator, The Innovation Factory, is refining its strategy to help capture more value, at both the earliest and latest stages of technology development and company creation.

You may also be interested in...



The Innovation Factory: Re-Thinking the Incubator Model

For many device start-ups, incubators have been critical to an early, efficient launch of their company. Unfortunately, the financial model behind incubators hasn't always been so generous to the incubators themselves. Now, a leading incubator, The Innovation Factory, is refining its strategy to help capture more value, at both the earliest and latest stages of technology development and company creation.

The Innovation Factory: Re-Tooling Device Start-Ups

These are tough times for medical device start-ups. Now a new company offers fresh approaches to company creation and financing that reduces risk for investors and entrepreneurs. The Innovation Factory is taking a new approach to device company creation, one that leverages resources for early-stage projects and reduces risk for investors. Its goal isn't just to provide support services but to actually launch the companies.

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel